GlycoMimetics, Inc. (GLYC)

GlycoMimetics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	0.01	0.08	1.16	10.16
Revenue Growth (YoY)	-	-86.67%	-93.53%	-88.59%	-
Gross Profit	-	0.01	0.08	1.16	10.16
Selling, General & Admin	18.25	19.21	19.09	17.12	16.74
Research & Development	14.26	20.07	28.39	47.49	44.93
Operating Expenses	32.51	39.29	47.48	64.61	61.67
Operating Income	-32.51	-39.28	-47.4	-63.45	-51.51
Interest & Investment Income	0.94	2.38	0.71	0.02	0.48
EBT Excluding Unusual Items	-31.57	-36.9	-46.69	-63.43	-51.03
Merger & Restructuring Charges	-7.53	-	-	-	-
Gain (Loss) on Sale of Assets	1.22	-	-	-	-
Pretax Income	-37.88	-36.9	-46.69	-63.43	-51.03
Net Income	-37.88	-36.9	-46.69	-63.43	-51.03
Net Income to Common	-37.88	-36.9	-46.69	-63.43	-51.03
Shares Outstanding (Basic)	64	63	53	51	46
Shares Outstanding (Diluted)	64	63	53	51	46
Shares Change (YoY)	1.79%	20.58%	2.10%	12.54%	5.70%
EPS (Basic)	-0.59	-0.58	-0.89	-1.23	-1.12
EPS (Diluted)	-0.59	-0.58	-0.89	-1.23	-1.12
Free Cash Flow	-31.11	-34.9	-46.54	-57.5	-39.31
Free Cash Flow Per Share	-0.48	-0.55	-0.89	-1.12	-0.86
Gross Margin	-	100.00%	100.00%	100.00%	100.00%
Operating Margin	-	-392752.93%	-63204.43%	-5470.69%	-506.84%
Profit Margin	-	-368994.20%	-62251.74%	-5468.98%	-502.09%
Free Cash Flow Margin	-	-349012.97%	-62055.57%	-4958.28%	-386.80%
EBITDA	-32.47	-39.12	-47.2	-63.18	-51.24
D&A For EBITDA	0.04	0.15	0.21	0.26	0.27
EBIT	-32.51	-39.28	-47.4	-63.45	-51.51

Updated Feb 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q